ReviewThe Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology2025
Phytochemicals as promising agents in Axl-targeted cancer treatment.
Review in The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Axl, a receptor tyrosine kinase, plays a critical role in various cellular processes, such as survival, proliferation, migration, and immune response regulation. Dysregulation of Axl, particularly its overexpression and activation, is implicated in several cancers, where it has been found to facilitate tumor growth, metastasis, and the development of resistance to chemotherapy. Consequently, the inhibition of Axl has garnered significant interest as a potential strategy for cancer treatment. Natural compounds, known for their structural diversity and inherent bioactivity, are a valuable resource for drug discovery. These compounds offer a vast array of chemical structures that can serve as potential inhibitors of Axl, thereby providing novel approaches to modulate its activity. Researchers have identified various natural compounds that exhibit inhibitory effects on Axl, which underscore their potential for developing effective therapies. This review strives to provide a comprehensive overview of natural compounds that have been identified as Axl inhibitors. It will examine the mechanisms through which these natural compounds exert their inhibitory effects on Axl and discuss their potential applications in therapeutic settings. By compiling and analyzing existing research, this review seeks to advance the understanding of natural compounds as viable candidates in the development of effective Axl-targeted therapies, ultimately contributing to improved outcomes in diseases marked by Axl dysregulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.